Treatment Of Advanced Non-small Cell Lung Cancer By Chemotherapy Combined With Autologous Cytokine-induced Killer Cells

Objective Biotherapy is becoming an effective combination method for cancer therapy. We evaluated the clinical efficacy of chemotherapy combined with CIK biotherapy to advanced non-small cell lung cancer (NSCLC).Methods 59 advanced NSCLC patients were fractionated group A (chemotherapy alone) and group B (chemotherapy plus CIK biotherapy). The host cellular immune function, quality of life(QOL), response rate, time to progression(TTP) and median survival time(MST) were compared between the two groups. CIK cells were induced from autologous peripheral mononuclear cells.Results Amounts and cytotoxic activity of CIK cells reached the peak between days14 to 21. The host immune function was increased and QOL was improved in patients treated by CIK biotherapy plus chemotherapy compared to patients treated by chemotherapy alone, the disease control rate (DCR) was higher, The time to progression (TTP) was longer, the median survival time (MST) was longer, the disease-free survival and overall survival is significantly prolonged. The ORR has no significant difference between the 2 groups.Conclusions It is safety to patients by autologous CIK cells transfusion. Chemotherapy combined with CIK cells has benefits for the patients suffering from advanced NSCLC, and there is advantage to chemotherapy alone in terms of QOL, DCR, TTP and survival.